Nearly double the time before disease progression
For patients with advanced lung cancer whose tumors have learned to resist the drugs designed to fight them, medicine has long offered only blunt alternatives. A large clinical trial published in The New England Journal of Medicine on October 20, 2025, now suggests that sacituzumab tirumotecan — an antibody-drug conjugate tested against standard chemotherapy in China and beyond — can nearly double the time before disease worsens and reduce the risk of death by 40 percent. In the long arc of oncology, this is the kind of result that quietly redraws the boundary between what is possible and what is not.
- Patients with EGFR-mutant lung cancer who exhaust their first targeted therapy face a grim narrowing of options — sac-TMT now challenges that wall directly.
- The Phase III OptiTROP-Lung04 trial showed median progression-free survival nearly doubling from 4.3 to 8.3 months, with 65.8% of sac-TMT patients alive at 18 months versus 48% on chemotherapy.
- Unlike combination regimens, this is a single drug delivering a targeted payload to tumor cells — and its side effects, led by mild mouth inflammation, were largely manageable with no serious lung or infusion complications.
- China's drug regulator has already approved sac-TMT as the only monotherapy for TKI-resistant EGFR-mutant lung cancer, signaling rapid institutional confidence in the trial's findings.
- Developer MSD is now running 15 global Phase III trials pairing sac-TMT with other agents across cancer types, suggesting this result is the opening move in a much larger therapeutic strategy.
A new drug has offered a measurable extension of life to patients with advanced lung cancer who have run out of first-line options. Sacituzumab tirumotecan, or sac-TMT, was tested in the Phase III OptiTROP-Lung04 trial against standard platinum-based chemotherapy, enrolling patients whose tumors carry EGFR mutations and had already developed resistance to tyrosine kinase inhibitors. The results, published October 20 in The New England Journal of Medicine, were led by Professor Zhang Li's team at Sun Yat-sen University Cancer Center in China.
The survival numbers were striking. Patients on sac-TMT went nearly twice as long before their disease progressed — 8.3 months versus 4.3 months — and at the 18-month mark, 65.8 percent were still alive compared to 48 percent on chemotherapy. The drug reduced the risk of death by 40 percent, and the benefit held across subgroups regardless of prior treatment history, metastasis location, or specific mutation type.
Sac-TMT works by binding to TROP2, a protein on tumor cell surfaces, and delivering a DNA-damaging payload directly into the cell. Because the payload can cross cell membranes, it also affects neighboring tumor cells that don't express TROP2 — a mechanism that may help explain its broad effectiveness. Crucially, it achieves this as a monotherapy, not a combination regimen, and its safety profile was largely tolerable: mild stomatitis was the most common side effect, with no cases of serious lung inflammation or infusion reactions.
China's National Medical Products Administration has already approved sac-TMT as the only monotherapy for this patient population — those who have failed TKI therapy with or without subsequent chemotherapy. Developed by Sichuan Kelun-Biotech and licensed globally to MSD in 2022, the drug is now the subject of 15 additional Phase III trials across multiple cancer types. For patients who had few places left to turn, the treatment landscape has meaningfully shifted.
A new drug has cleared a significant hurdle in the treatment of advanced lung cancer, offering patients who have exhausted their first-line options a measurable chance at longer survival. Sacituzumab tirumotecan, known as sac-TMT, was tested against standard chemotherapy in a large Phase III trial called OptiTROP-Lung04, and the results were published on October 20 in The New England Journal of Medicine—one of the world's most selective medical journals.
The trial enrolled patients with a specific type of lung cancer: those carrying EGFR mutations who had already progressed through tyrosine kinase inhibitor therapy, the current standard first-line treatment. These are patients at a difficult juncture. Their tumors have developed resistance to the targeted drugs that initially worked. Historically, the next step has been platinum-based chemotherapy, a blunt instrument that extends survival modestly but comes with substantial toxicity. The OptiTROP-Lung04 study, led by Professor Zhang Li's team at Sun Yat-sen University Cancer Center in China, asked whether a newer class of drug—an antibody-drug conjugate that targets TROP2 on tumor cells—could do better.
The numbers tell a story of meaningful improvement. After a median follow-up of 18.9 months, patients receiving sac-TMT had a median progression-free survival of 8.3 months, compared to 4.3 months for those on chemotherapy. That is nearly double the time before disease progression. The survival advantage was even starker: at 18 months, 65.8 percent of patients on sac-TMT were still alive, versus 48 percent on chemotherapy. The hazard ratio for death was 0.60, meaning the drug reduced the risk of death by 40 percent. These benefits held across all major patient subgroups tested—regardless of which prior TKI they had received, whether they had brain or liver metastases, or which specific EGFR mutation they carried.
What makes this result clinically significant is not just the magnitude of benefit but the context in which it was achieved. This is a monotherapy—a single drug, not a combination regimen. Sac-TMT works by binding to TROP2, a protein on the surface of tumor cells, and delivering a topoisomerase I inhibitor payload directly into the cell. The drug induces DNA damage that triggers cell death, and because the payload is membrane-permeable, it can also kill adjacent tumor cells that don't express TROP2. The mechanism is elegant, and the trial design was rigorous: randomized, open-label, multicenter, with progression-free survival assessed by a blinded independent review committee.
The safety profile was manageable. Stomatitis—inflammation of the mouth—was the most common adverse event, but most cases were mild. Only 4.8 percent of patients experienced grade 3 stomatitis, and no grade 4 cases were reported. There were no cases of interstitial lung disease or pneumonitis, complications that can be serious with some cancer drugs. Only one infusion-related reaction occurred, and it was grade 2. The incidence of eye-surface toxicity was low. For patients already burdened by advanced cancer and its treatment, a drug that works without imposing severe new harms is a genuine advance.
The approval pathway has already moved quickly. Based on these results, China's National Medical Products Administration approved sac-TMT for patients with EGFR-mutant advanced non-squamous lung cancer who have progressed after TKI therapy. Notably, sac-TMT is now the only approved monotherapy option for this population—those who have failed TKI alone, and those who have failed TKI followed by platinum chemotherapy. The drug was developed by Sichuan Kelun-Biotech, which licensed global rights outside Greater China to MSD in 2022. MSD is now running 15 Phase III trials of sac-TMT in combination with other agents across multiple cancer types. The company has positioned this as a potential cornerstone therapy, and the evidence from OptiTROP-Lung04 supports that ambition. For patients with TKI-resistant EGFR-mutant lung cancer, the treatment landscape has shifted.
Notable Quotes
OptiTROP-Lung04 confirms sac-TMT as the first treatment option as a monotherapy to deliver clear dual benefits in both progression-free and overall survival following EGFR-TKI progression, establishing itself as a new standard of care.— Professor Shengxiang Ren, Department of Oncology, Shanghai Pulmonary Hospital
The Hearth Conversation Another angle on the story
Why does this trial matter so much? Isn't there already treatment after TKI failure?
There is, but it's chemotherapy—and it's not very good. Median progression-free survival with platinum doublets is around four months. Patients and doctors have been waiting for something better.
So sac-TMT doubles that survival time?
It nearly doubles it—8.3 months versus 4.3. And it does it as a monotherapy, which means fewer drugs, fewer interactions, potentially fewer side effects.
What's the mechanism? How does it actually kill the cancer?
It's an antibody-drug conjugate. The antibody finds TROP2 on tumor cells, binds to it, gets pulled inside, and releases a topoisomerase inhibitor that breaks DNA. The clever part is that the payload can leak out and kill neighboring cells too.
That sounds like it could be toxic.
You'd think so, but the safety data is clean. Mouth sores were the main issue, and they were mostly mild. No lung damage, no serious infusion reactions. For a drug that extends survival this much, the trade-off is favorable.
Is this a cure?
No. Median progression-free survival is still less than nine months. But in advanced cancer, extending survival and delaying progression by four months while maintaining quality of life is substantial. It buys time.
What happens when this drug stops working?
That's the next question. The trial doesn't tell us. But the fact that it's approved as a monotherapy option before chemotherapy suggests doctors might use it first, then move to chemotherapy if needed. That's a shift in sequencing.